Clinical Supply Chain
Forecasting, depot strategy, comparator sourcing and the operational decisions that keep a study supplied without stranding capital in inventory.
Biotechnology & Pharmaceutical
A Basel-based consulting firm working with biotechnology and pharmaceutical companies on clinical supply chain and clinical trials — the decisions where getting it wrong costs a programme its timeline.
We serve companies of every size across the industry. Two areas are where our capability is genuinely differentiated, and where most of our work sits.
Forecasting, depot strategy, comparator sourcing and the operational decisions that keep a study supplied without stranding capital in inventory.
Study design feasibility, site and vendor strategy, and the programme-level trade-offs that decide whether a timeline is credible.
When strategic and insight-driven decisions are aligned, the best possible patient outcome, innovation and shareholder value follow.
That is not a slogan about caring more. It is a claim about sequence: the industry's hardest problems are decision problems, and most programmes lose time not to execution but to decisions that were made on thin evidence and then revisited.
Evidence sized to the decision, not a dashboard nobody opens twice.
Advisory grounded in what your organisation will actually operate.
Senior people who have run these programmes, in the room throughout.
We are based in the centre of European pharmaceutical manufacturing — close to the companies, the regulators and the supply chains our work depends on. That proximity is not incidental; it is why we can be in the room quickly when a decision cannot wait.
A critical element of post-engagement success is a genuinely collaborative working relationship, from initiation through to closure. It is the difference between a deck that gets read and a decision that gets made.
Our value-add is designed to extend past the scope line — which is also, plainly, what raises the probability that the work succeeds after we leave.
Highly experienced and deliberately diverse, with real industry tenure behind the advice. The composition is the point: a fresh, collaborative approach that drives transformational impact without giving up access to top-tier expertise.
Life Sciences Accelerated will be engaging in the Science Based Targets initiative (SBTi) with the formal target validation service as soon as possible.
The Science Based Targets initiative (SBTi) is a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis.
We will tell you honestly whether it is work we should be doing — and who else you should talk to if it is not.